Combination chemotherapy for recurrent prostatic cancer with estracyt and etoposide

The effectiveness of combination chemotherapy with estracyt and etoposide, which would enable ambulatory care, was studied in a multi-center collaborative study. Eighteen patients with recurrent prostatic cancer after endocrine therapy were administered estracyt 560 mg orally daily in four equal dos...

Full description

Saved in:
Bibliographic Details
Published inJapanese Journal of Chemotherapy Vol. 49; no. 9; pp. 557 - 561
Main Authors Nakata, Joujiro, Suzuki, Hidenori, Kiyota, Hiroshi, Wada, Tetsuro, Ueda, Masataka, Ohnisi, Tetsuro, Ohoishi, Yukihiko, Yamazaki, Haruki, Onodera, Syouichi, Hayashi, Norihiro, Abe, Kazuhiro, Ikemoto, Isao
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 2001
公益社団法人 日本化学療法学会
Subjects
Online AccessGet full text
ISSN1340-7007
1884-5886
DOI10.11250/chemotherapy1995.49.557

Cover

More Information
Summary:The effectiveness of combination chemotherapy with estracyt and etoposide, which would enable ambulatory care, was studied in a multi-center collaborative study. Eighteen patients with recurrent prostatic cancer after endocrine therapy were administered estracyt 560 mg orally daily in four equal doses and 100 mg/m2/day etoposide i.v. for 3 days, every 4 weeks. The duration of treatment was 104 days on average (maximum 360 days). Eleven (61.1%) patients received 3 courses of treatment. After the end of 3 courses, performance status (PS) was improved in 2 patients, unchanged in 8, and worsened in only one patient, with improvement of pain being observed in 8 patients. Partial response (PR) was attained in 1 patient, no change (NC) in 5 and progressive disease (PD) in 5; there were 6 unevaluable patients, with the effectiveness rate being 9.1%. The rate of PR+NC was 54.5%, when cases with ability of ambulatory care keeping quality of life (QOL) were included in the cases of NC. The effectiveness of this combination chemotherapy, based on PSA levels only was 45.4% in more than PR and 81.8% in PR+NC. This regimen was more effective in patients less than 74 years old with comparatively good PS. In addition, this regimen could be satisfactorily administered on an ambulatory basis because hematological adverse reactions were scarce. This regimen can be repeatedly administered to ambulatory patients thereby maintaining that good QOL, however, the proximity effect is not so large.
ISSN:1340-7007
1884-5886
DOI:10.11250/chemotherapy1995.49.557